The need for third-line treatment in non-small cell lung cancer: an overview of new options.

Syrigos KN; Saif MW; Karapanagiotou EM; Oikonomopoulos G; De Marinis F

首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >The need for third-line treatment in non-small cell lung cancer: an overview of new options.

【24h】

The need for third-line treatment in non-small cell lung cancer: an overview of new options.

机译：非小细胞肺癌对三线治疗的需求：新选择的概述。

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

As a result of improved effectiveness of first-, second-line and maintenance therapeutic regimens in non-small cell lung cancer, there is need for new options as third-line treatment. Erlotinib and gefitinib are currently the only drugs of proven efficacy in the third-line setting. Chemotherapy drugs, such as pemetrexed, are being investigated, as are many new agents, such as cetuximab, sunitinib, sorafenib, everolimus, enzastaurin, afilbercept. These novel targeted therapies seem to improve response rates and progression-free survival and their toxicity is tolerable. In an effort to prolong survival while maintaining quality of life, large prospective studies are needed to examine the effectiveness and safety of third-line regimens in these patients.

机译：由于一线，二线和维持性治疗方案在非小细胞肺癌中改善的有效性，因此需要新的选择作为三线治疗。厄洛替尼和吉非替尼目前是三线治疗中唯一被证明具有疗效的药物。正在研究化学疗法药物，例如培美曲塞，以及许多新药物，例如西妥昔单抗，舒尼替尼，索拉非尼，依维莫司，恩扎他林，阿非西普。这些新颖的靶向疗法似乎可以提高缓解率和无进展生存期，并且其毒性是可以忍受的。为了延长生存时间并保持生活质量，需要进行大量前瞻性研究来检查三线方案对这些患者的有效性和安全性。

著录项

来源
《Anticancer Research: International Journal of Cancer Research and Treatment》 |2011年第2期|共11页
作者
Syrigos KN; Saif MW; Karapanagiotou EM; Oikonomopoulos G; De Marinis F;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. The need for third-line treatment in non-small cell lung cancer: an overview of new options. [J] . Syrigos KN, Saif MW, Karapanagiotou EM, Anticancer Research: International Journal of Cancer Research and Treatment . 2011,第2期

机译：非小细胞肺癌对三线治疗的需求：新选择的概述。
2. A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib vs Chemotherapy Alone as Second- or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung Cancer [J] . Hai-ying Wang, Jun-feng Chu, Yan Zhao, Cancer Management and Research . 2020,第4期

机译：一种试验化疗的安全性和疗效加上anlotinib与化疗单独作为前进的非小细胞肺癌的二线或第三线救死治疗
3. Prognostic factors affecting survival in third-line treatment of advanced non-small cell lung cancer: Retrospective cohort study [J] . Ferit ASLAN, Umut DEM?RC?, Derya KIZILG?Z, Journal of surgery and medicine. . 2020,第2期

机译：影响高级非小细胞肺癌三线治疗生存的预后因素：回顾性队列研究
4. SAHA Treatment Reveals the Link between Histone Lysine Acetylation and Proteome in Non-small Cell Lung Cancer A549 Cells [C] . Quan Wu, Weiqing Xu, Lejie Cao, ASMS Conference on Mass Spectrometry and Allied Topics . 2014

机译：Saha治疗揭示了非小细胞肺癌A549细胞中组蛋白赖氨酸乙酰化和蛋白质组之间的联系
5. The cost effectiveness of screening for early stage lung cancer and the testing and treatment of molecular subgroups among non-small cell lung cancer patients in the province of ontario, canada [D] . Thao, Mallory. 2014

机译：加拿大安大略省非小细胞肺癌患者早期肺癌筛查的成本效益及分子亚群的检测和治疗
6. Treatment Paradigms for Patients with Metastatic Non-Small Cell Lung Cancer Squamous Lung Cancer: First Second and Third-Line [O] . Abdulaziz Al-Farsi, Peter Michael Ellis 2014

机译：转移性非小细胞肺癌鳞癌的治疗范例：一线二线和三线
7. Treatment Paradigms for Patients with Metastatic Non-Small Cell Lung Cancer, Squamous Lung Cancer: First, Second, and Third-Line [O] . Abdulaziz Al-Farsi, Peter Michael Ellis 2014

机译：转移性非小细胞肺癌，鳞状肺癌患者的治疗范式：一线，二线和三线

The need for third-line treatment in non-small cell lung cancer: an overview of new options.

摘要

著录项

相似文献

相关主题

期刊订阅